2025年美国临床肿瘤学会膀胱癌亮点

2025 ASCO Bladder Cancer Highlights.

作者信息

Emrich Gerhard

出版信息

Oncol Res Treat. 2025 Jul 24:1-6. doi: 10.1159/000547631.

Abstract

The potential impact of neoadjuvant therapy and the role of circulating tumor DNA (ctDNA) analysis were key discussion points at the 2025 ASCO Annual Meeting. Updated results from the phase 3 EV-302 trial were also presented with impressive outcomes among patients who experienced a complete response to enfortumab vedotin plus pembrolizumab.

摘要

新辅助治疗的潜在影响以及循环肿瘤DNA（ctDNA）分析的作用是2025年美国临床肿瘤学会年会的关键讨论要点。3期EV-302试验的最新结果也已公布，在接受恩杂鲁胺联合派姆单抗治疗后获得完全缓解的患者中取得了令人瞩目的成果。